Trial Profile

A phase I trial of ENV105 with Tagrisso for treatment of lung cancer

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 22 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carotuximab (Primary) ; Osimertinib (Primary)
Indications Lung cancer
Focus Adverse reactions
Sponsors Kairos Pharma

Most Recent Events

22 Feb 2022 New trial record
15 Feb 2022 According to a Kairos Pharma media release, this trial is expected to start in 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com